You searched for drug development - Page 171 of 213

In Depth 17 Oct 2017

Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis

Though the psoriasis market is teeming with effective products, companies have developed ways to devise new, more effective modes of treatment. Psoriasis is a common autoimmune disorder that affects the skin, often causing patches of dry, itchy, and painful lesions. In severe cases, people can develop psoriatic arthritis, which can lead to painful inflammation in […]

October 17, 2017 - 7 minutesmins - By Diana Kwon

bc platforms biogen microsoft multiple sclerosis

News and Trends 16 Oct 2017

Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis

BC Platforms and Microsoft will be working with Biogen and the Accelerated Cure Project to study the genetics of multiple sclerosis and accelerate research. The Swiss firm BC Platforms has built a platform to facilitate access to and analysis of large volumes of genomic and clinical data. Since September, the company has been collaborating with Microsoft, […]

October 16, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

antibiotic resistance inhibitor antabio 1

News and Trends 16 Oct 2017

French Biotech Lifted by €7M Series A to Develop New Antibiotics

Antabio has taken a step towards tackling antibiotic resistance by securing a €7.3M Series A. The funding will accelerate the company’s candidate through a Phase I clinical trial. Antabio is a French biopharma that focuses on one of the world’s biggest crises – antibiotic resistance. The company has raised €7.3M in Series A of fundraising, which it will use to […]

October 16, 2017 - 3 minutesmins - By Alex Dale

News and Trends 16 Oct 2017

Interview: On the Future of iPS Cells and why Partnering is so Important in this Field

In our first part of the interview with Dr David Hallett, Executive Vice President at Evotec, we discussed the uniqueness of Induced Pluripotent Stem Cells (iPS Cells), novel developments occurring in iPS Cell research, and the challenges researchers face. Let us have a short recap of what we have learned so far: iPS Cells were […]

October 16, 2017 - 9 minutesmins - By External Contributor

More News! 13 Oct 2017

German Biotech Gets €47M To Treat Painful Inflammatory Disease

InflaRx has raised $55M (€47M) in a Series D fundraising in order to get its lead anti-inflammatory drug, IFX-1, through late-stage development. A year after its €31M Series C, InflaRx is closing a Series D round. The company has raised a total of $55M (€47M) from a team of US investors co-led by Bain Capital Life Sciences, […]

October 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Startup Scout 13 Oct 2017

This French Biotech is Taking On CNS Diseases of the Young and the Elderly

This week we’re in Castres in the South of France to visit Neurolixis. This biotech is taking on diseases of the CNS, such as Parkinson’s, depression and schizophrenia. Mission: Neurolixis is tackling CNS and mood diseases, a number of which lack effective treatment options at the moment. The biotech currently has two candidate drugs undergoing […]

October 13, 2017 - 2 minutesmins - By Alex Dale

News and Trends 11 Oct 2017

Scottish Scientists Could Hold the Key to Unlocking Parkinson’s Disease

A decade of work has culminated in researchers reconstructing a protein that is key to defending the brain against Parkinson’s disease. Researchers at the University of Dundee have made a breakthrough by uncovering the 3D structure of an enzyme, PINK1, that can protect the brain against Parkinson’s disease. The disease is characterised by the degeneration […]

October 11, 2017 - 3 minutesmins - By Alex Dale

Best in Biotech 10 Oct 2017

Buongiorno Biotech! Top 4 Companies Making Milan Europe’s Next Biotech Hub

Italy may not be the first country that comes to mind when you think of biotech, but the sun is rising in a new dawn for Italian biotechs that are taking their respective fields by storm. Italy is home to a lot of things; food, fashion, Ferraris… but it is now quickly growing a biotech scene […]

October 10, 2017 - 7 minutesmins - By Alex Dale

Nobel Prize in Chemistry 2017 Richard Henderson Heptares Therapeutics

News and Trends 5 Oct 2017

British Biotech Founder Receives the Nobel Prize in Chemistry 2017

Richard Henderson, awarded the Nobel Prize in Chemistry 2017, founded Heptares Therapeutics to apply his Nobel-winning technology to discover new medicines. This year’s Nobel Prize in Chemistry has been awarded to Jacques Dubochet, Joachim Frank and Richard Henderson for the development of cryo-electron microscopy. This technology, now widely used in structural biology labs, is considered a stepping […]

October 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Oct 2017

Ablynx Launches $175M IPO on Wall Street After Phase III Success

Fresh from announcing positive Phase III results, Ablynx has wasted no time in filing a $175M (€148M) IPO to continue developing its nanobodies technology. On Monday, the Belgian biotech shared the news that its nanobody, caplacizumab, received encouraging results for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a life-threatening blood disorder. This news boosted the company’s […]

October 4, 2017 - 2 minutesmins - By Alex Dale

ulf grawunder nbe therapeutics interview

Interview 4 Oct 2017

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what NBE is doing differently from its predecessors. Ever since the first antibody-drug conjugate (ADC) was approved in 2001, there has been a lot of excitement about the technology. “Some people even referred to ADCs as a ‘magic bullet,’” recalls Ulf […]

October 4, 2017 - 5 minutesmins - By Evelyn Warner

sobi hemophilia clotting factor alprolix

News and Trends 2 Oct 2017

Belgian Biotech Breaks New Ground in Fight Against Life-Threatening Blood Disorder

Ablynx has triumphed where others have fallen by receiving positive Phase III results for the treatment of a dangerous blood disorder with caplacizumab. Ablynx develops nanobodies, molecules with the specificity of antibodies but much smaller in size. Its product, caplacizumab, has received encouraging results for the treatment of the life-threatening autoimmune blood disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which […]

October 2, 2017 - 3 minutesmins - By Alex Dale

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: drug development

Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis

Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis

French Biotech Lifted by €7M Series A to Develop New Antibiotics

Interview: On the Future of iPS Cells and why Partnering is so Important in this Field

German Biotech Gets €47M To Treat Painful Inflammatory Disease

This French Biotech is Taking On CNS Diseases of the Young and the Elderly

Scottish Scientists Could Hold the Key to Unlocking Parkinson’s Disease

Buongiorno Biotech! Top 4 Companies Making Milan Europe’s Next Biotech Hub

British Biotech Founder Receives the Nobel Prize in Chemistry 2017

Ablynx Launches $175M IPO on Wall Street After Phase III Success

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

Belgian Biotech Breaks New Ground in Fight Against Life-Threatening Blood Disorder

Subscribe to our newsletter to get the latest biotech news!